Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

DNMT3A mutations define a unique biological and prognostic subgroup associated with cytotoxic T cells in PTCL-NOS

Blood (2022) 140 (11): 1278–1290.

https://doi.org/10.1182/blood.2021015019

Published: 2022

Includes: Supplemental data

Journal Articles

Reproducing the molecular subclassification of peripheral T-cell lymphoma–NOS by immunohistochemistry

Blood (2019) 134 (24): 2159–2170.

https://doi.org/10.1182/blood.2019000779

Published: 2019

Includes: Supplemental data

Journal Articles

Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia

Matthew Lunning, Julie Vose, Loretta Nastoupil, Nathan Fowler, Jan A. Burger, William G. Wierda, Marshall T. Schreeder, Tanya Siddiqi, Christopher R. Flowers, Jonathon B. Cohen, Peter Sportelli, Hari P. Miskin, Michael S. Weiss, Susan O’Brien

Blood (2019) 134 (21): 1811–1820.

https://doi.org/10.1182/blood.2019002118

Published: 2019

Includes: Supplemental data

Journal Articles

Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma

Blood (2019) 133 (15): 1664–1676.

https://doi.org/10.1182/blood-2018-09-872549

Published: 2019

Includes: Supplemental data

Journal Articles

Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma

Ann S. LaCasce, R. Gregory Bociek, Ahmed Sawas, Paolo Caimi, Edward Agura, Jeffrey Matous, Stephen M. Ansell, Howland E. Crosswell, Miguel Islas-Ohlmayer, Caroline Behler, Eric Cheung, Andres Forero-Torres, Julie Vose, Owen A. O’Connor, Neil Josephson, Yinghui Wang, Ranjana Advani

Blood (2018) 132 (1): 40–48.

https://doi.org/10.1182/blood-2017-11-815183

Published: 2018

Includes: Supplemental data

Journal Articles

Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets

Blood (2017) 130 (16): 1819–1831.

https://doi.org/10.1182/blood-2017-02-767335

Published: 2017

Includes: Supplemental data

Journal Articles

Crebbp loss cooperates with Bcl2 overexpression to promote lymphoma in mice

Blood (2017) 129 (19): 2645–2656.

https://doi.org/10.1182/blood-2016-08-733469

Published: 2017

Includes: Supplemental data

Journal Articles

Brentuximab Vedotin Plus Bendamustine: A Highly Active Salvage Treatment Regimen for Patients with Relapsed or Refractory Hodgkin Lymphoma

Ann S. LaCasce, MD, Gregory Bociek, Ahmed Sawas, Paolo F. Caimi, MD, Edward Agura, Jeffrey Matous, Stephen Ansell, MD PhD, Howland Crosswell, MD, Miguel Islas-Ohlmayer, Caroline Behler, Eric Cheung, Andres Forero-Torres, Julie Vose, Owen A. O'Connor, MD, Neil Josephson, Ranjana Advani

Blood (2015) 126 (23): 3982.

https://doi.org/10.1182/blood.V126.23.3982.3982

Published: 2015

Journal Articles

Clinical Characteristics and Outcomes of Patients with Hodgkin Lymphoma with Central Nervous System Involvement: An International Multicenter Collaboration

Chan Yoon Cheah, MBBS DMedSc, Paul J Broeckelmann, MD, Alison J Moskowitz, MD, Andreas Engert, MD, Mats Jerkeman, MD PhD, Tarec Christoffer El-Galaly, Julie Vose, Diego Villa, MDMPH, Joseph M. Connors, MD, Tatyana Feldman, MD, Dai Chihara, MD PhD, Chelsea C Pinnix, MDPhD, Sarah A Milgrom, MD, Bouthaina S. Dabaja, MD, Yasuhiro Oki, MD, Michelle A. Fanale, MD

Blood (2015) 126 (23): 3865.

https://doi.org/10.1182/blood.V126.23.3865.3865

Published: 2015

Journal Articles

Ublituximab + TGR-1202 Demonstrates Activity and a Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL: Phase I Results

Matthew A. Lunning, DO, Julie Vose, Nathan Fowler, MD, Loretta Nastoupil, MD, Jan A. Burger, MD PhD, William Wierda, MD PhD, Marshall T. Schreeder, MD, Tanya Siddiqi, MD, Christopher Flowers, MD, Jonathon B. Cohen, MD, Susan Blumel, RN, BSN, Myra Miguel, RN, Kathy Cutter, RN, BSN, Emily K. Pauli, BMBS, PharmD, Ryan Handy, BS, Peter Sportelli, Hari P. Miskin, MS, Michael S. Weiss, Susan O'Brien, MD

Blood (2015) 126 (23): 1538.

https://doi.org/10.1182/blood.V126.23.1538.1538

Published: 2015

Journal Articles

IDH2 R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma

Blood (2015) 126 (15): 1741–1752.

https://doi.org/10.1182/blood-2015-05-644591

Published: 2015

Includes: Supplemental data

Journal Articles

Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis

Blood (2014) 124 (15): 2354–2361.

https://doi.org/10.1182/blood-2014-05-578963

Published: 2014

Includes: Supplemental data

Journal Articles

Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma

Blood (2014) 123 (19): 2915–2923.

https://doi.org/10.1182/blood-2013-11-536359

Published: 2014

Includes: Supplemental data

Journal Articles

Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project

Wing-yan Au, Dennis D. Weisenburger, Tanin Intragumtornchai, Shigeo Nakamura, Won-Seog Kim, Ivy Sng, Julie Vose, James O. Armitage, Raymond Liang, for the International Peripheral T-Cell Lymphoma Project

Blood (2009) 113 (17): 3931–3937.

https://doi.org/10.1182/blood-2008-10-185256

Published: 2009

Includes: Supplemental data

Journal Articles

Molecular Signatures Implicate Innate Immune Cells, Fibrosis, and Angiogenesis in Survival Following R-CHOP Treatment of Diffuse Large B Cell Lymphoma

Blood (2008) 112 (11): 475.

https://doi.org/10.1182/blood.V112.11.475.475

Published: 2008

Journal Articles

Gene Expression Signatures Predict Overall Survial in Diffuse Large B Cell Lymphoma Treated with Rituximab and Chop-Like Chemotherapy.

Georg Lenz, MD, George Wright, PhD, Sandeep Dave, MD, Alexander Kohlmann, PhD, Wenming Xiao, PhD, John Powell, MS, Hong Zhao, Weihong Xu, Randy D. Gascoyne, MD, Joseph M. Connors, MD, Lorraine May, MD, Dennis D. Weisenburger, MD, Tim Greiner, MD, Julie Vose, MD, James O. Armitage, MD, Javeed Iqbal, MD, Martin Bast, MD, Kai Fu, MD, Elias Campo, MD, Emili Montserrat, MD, Armando Lopez-Guillermo, MD, Pedro Jares, MD, Antonio Martinez, MD, Betty Gibbs, MD, Lisa M. Rimsza, MD, Richard I. Fisher, MD, Rita M. Braziel, MD, Ray Tubbs, MD, James Cook, MD, Brad Pohlman, MD, John Sweetenham, MD, Gunhild Troen, MD, Erlend B. Smeland, MD, Jan Delabie, MD, Stein Kvaloy, MD, Harald Holte, MD, Elaine S. Jaffe, MD, Wyndham H. Wilson, MD, Nicole Grant, MD, Elena Hartmann, MD, Andreas Rosenwald, MD, German Ott, MD, Hans-Konrad Muller-Hermelink, MD, T. Andrew Lister, MD, Mickey Williams, PhD, Lothar Wieczorek, PhD, Wing C. Chan, MD, Louis M. Staudt, MD, PhD

Blood (2007) 110 (11): 348.

https://doi.org/10.1182/blood.V110.11.348.348

Published: 2007

Journal Articles

Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival

Blood (2007) 109 (11): 4599–4606.

https://doi.org/10.1182/blood-2006-08-039859

Published: 2007

Journal Articles

Long-Term Follow-Up of Patients Treated in a Phase 2 Trial with MyVax® Personalized Immunotherapy (Recombinant Id-KLH with GM-CSF) after Chemotherapy as Initial Treatment for Follicular Non-Hodgkin’s Lymphoma (NHL).

John M. Timmerman, Julie Vose, Ronald Levy, Martha Mayo, Dan Denney

Blood (2005) 106 (11): 2438.

https://doi.org/10.1182/blood.V106.11.2438.2438

Published: 2005

Journal Articles

A Phase II Study of Enzastaurin, a Protein Kinase C-β (PKCβ) Inhibitor, in the Treatment of Relapsed Diffuse Large B-Cell Lymphoma (DLBCL).

Michael Robertson, Brad Kahl, Julie Vose, Sven de Vos, Mary Laughlin, Patrick Flynn, Kendrith Rowland, Jose Cruz, Stuart Goldberg, Christelle Darnstein, Nathan Enas, Donna Neuberg, Kerry Savage, Donald Thornton, Christopher Slapak, Margaret Shipp

Blood (2005) 106 (11): 934.

https://doi.org/10.1182/blood.V106.11.934.934

Published: 2005

Journal Articles

Reduced Intensity vs Myeloablative Conditioning for HLA Matched Sibling Transplantation in Follicular Lymphoma.

Koen Van Besien, Jeanette Carreras, Mei-Jie Zhang, Julie Vose, Hillard Lazarus, Christopher Bredeson, Parameswaran Hari

Blood (2005) 106 (11): 656.

https://doi.org/10.1182/blood.V106.11.656.656

Published: 2005

NARROW

DNMT3A mutations define a unique biological and prognostic subgroup associated with cytotoxic T cells in PTCL-NOS

Reproducing the molecular subclassification of peripheral T-cell lymphoma–NOS by immunohistochemistry

Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia

Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma

Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma

Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets

Crebbp loss cooperates with Bcl2 overexpression to promote lymphoma in mice

Brentuximab Vedotin Plus Bendamustine: A Highly Active Salvage Treatment Regimen for Patients with Relapsed or Refractory Hodgkin Lymphoma

Clinical Characteristics and Outcomes of Patients with Hodgkin Lymphoma with Central Nervous System Involvement: An International Multicenter Collaboration

Ublituximab + TGR-1202 Demonstrates Activity and a Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL: Phase I Results

IDH2 R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma

Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis

Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma

Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project

Molecular Signatures Implicate Innate Immune Cells, Fibrosis, and Angiogenesis in Survival Following R-CHOP Treatment of Diffuse Large B Cell Lymphoma

Gene Expression Signatures Predict Overall Survial in Diffuse Large B Cell Lymphoma Treated with Rituximab and Chop-Like Chemotherapy.

Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival

Long-Term Follow-Up of Patients Treated in a Phase 2 Trial with MyVax® Personalized Immunotherapy (Recombinant Id-KLH with GM-CSF) after Chemotherapy as Initial Treatment for Follicular Non-Hodgkin’s Lymphoma (NHL).

A Phase II Study of Enzastaurin, a Protein Kinase C-β (PKCβ) Inhibitor, in the Treatment of Relapsed Diffuse Large B-Cell Lymphoma (DLBCL).

Reduced Intensity vs Myeloablative Conditioning for HLA Matched Sibling Transplantation in Follicular Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only